- Home
- YI vs CRVO Comparison
YI vs CRVO Comparison
Compare YI & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- CRVO
- Stock Information
- Founded
- YI 2010
- CRVO 2001
- Country
- YI China
- CRVO United States
- Employees
- YI N/A
- CRVO N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- CRVO Health Care
- Exchange
- YI Nasdaq
- CRVO Nasdaq
- Market Cap
- YI 70.0M
- CRVO 67.4M
- IPO Year
- YI N/A
- CRVO N/A
- Fundamental
- Price
- YI $7.32
- CRVO $8.98
- Analyst Decision
- YI
- CRVO Strong Buy
- Analyst Count
- YI 0
- CRVO 7
- Target Price
- YI N/A
- CRVO $19.33
- AVG Volume (30 Days)
- YI 10.6K
- CRVO 195.5K
- Earning Date
- YI 08-28-2025
- CRVO 08-08-2025
- Dividend Yield
- YI N/A
- CRVO N/A
- EPS Growth
- YI N/A
- CRVO N/A
- EPS
- YI N/A
- CRVO N/A
- Revenue
- YI $1,984,717,013.00
- CRVO $9,308,215.00
- Revenue This Year
- YI N/A
- CRVO N/A
- Revenue Next Year
- YI N/A
- CRVO N/A
- P/E Ratio
- YI N/A
- CRVO N/A
- Revenue Growth
- YI N/A
- CRVO 15.14
- 52 Week Low
- YI $4.15
- CRVO $1.80
- 52 Week High
- YI $12.60
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- YI 42.76
- CRVO 68.10
- Support Level
- YI $7.10
- CRVO $7.81
- Resistance Level
- YI $7.65
- CRVO $8.60
- Average True Range (ATR)
- YI 0.18
- CRVO 0.74
- MACD
- YI 0.01
- CRVO 0.24
- Stochastic Oscillator
- YI 28.27
- CRVO 76.31
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.